Automated purification and amplification workflow submitted for FDA EUA*
Facing a sustained need for SARS-CoV-2 testing for both diagnostic and screening applications, many organizations are looking to expand or create testing capacity. For existing diagnostic labs, scale up challenges include limited supplies of instruments and reagents as well as a shortage of laboratory technologists and finite lab space.
LGC, Biosearch Technologies offers a SARS-CoV-2 detection platform with the potential to transform your lab’s capacity. Our high-throughput RT-PCR testing system, submitted for FDA EUA, can process from 4,500 up to 35,000 patient tests per day on a single platform.
Ready to increase
The Biosearch Technologies SARS-CoV-2 testing system from LGC
Biosearch Technologies’ SARS-CoV-2 testing workflow is an optimized bundle with hardware, reagents, consumables and software.
The footprint-friendly IntelliQube™ (qPCR) and Hydrocycler2™ (end-point PCR) platforms.
Biosearch Technologies’ validated SARS-CoV-2 reagents, enzymes, and probe and primer sets.
A dedicated customer service representative who ensures that your supply, hardware, and service needs are anticipated and met.
Testing capacity can be expanded from hundreds or thousands of samples to as many as 35,000 samples per day with minimal need for additional staff, instrumentation, or lab space.
Ready to increase testing throughput?